Greenwich, CT–In a sharp escalation of shareholder activism, Soleus Capital Management, L.P., a healthcare-focused investment firm holding over 10% of Theratechnologies Inc. (NASDAQ: THTX), has publicly urged the company’s Board of Directors to accept a proposed acquisition offer.
In a letter sent to the board, Soleus Capital endorsed a newly announced all-cash acquisition offer from Future Pak, LLC, priced at $3.51 per share. This represents a 163% premium over Theratechnologies’ April 10th closing price.
“The Future Pak offer provides a compelling, immediate return to shareholders that far exceeds the potential value of remaining a standalone entity,” Soleus wrote in the letter. The firm emphasized that the premium and structure of the offer mark it as a superior strategic option.
Soleus Capital, headquartered in Greenwich, Connecticut, manages a range of investment vehicles focused on the life sciences sector, including biotech, medtech, and genomics. The firm has built a reputation for identifying undervalued companies in the healthcare space and advocating for shareholder-aligned outcomes.
It remains to be seen how Theratechnologies’ board will respond to the public pressure from one of its largest shareholders.
